Matches in Nanopublications for { ?s ?p "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_assertion description "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645888.RAaW_8hku7Vwm-2-s086q1QfJV9SPQNywgTEsFylD1kc4130_provenance.
- assertion description "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_assertion description "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1056027.RAQp7fBNTRP25K4cl2X0qXCZS0bpK_qZozNcUO3zNVTJE130_provenance.
- NP645908.RA-7y3HoplylqtYzswUG7ui0XcGOf2KQshqAz_Z0h4O48130_assertion description "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645908.RA-7y3HoplylqtYzswUG7ui0XcGOf2KQshqAz_Z0h4O48130_provenance.
- NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_assertion description "[Treatment of established and patient-derived pancreatic cancer cell lines with the MEK1/2 inhibitor trametinib (GSK1120212) inhibited proliferation, and addition of the EGFR/HER2 inhibitor lapatinib enhanced the inhibition elicited by trametinib in three of eight cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1056016.RA0hclecFn7k9SMts4qq9WEBLp8IevnJvHjOIF837ITMQ130_provenance.